DOCSLIB.ORG

A Systematic Review and Meta-Analysis of the in Vivo Haemodynamic Effects of ∆9-Tetrahydrocannabinol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Systematic Review and Meta-Analysis of the in Vivo Haemodynamic Effects of ∆9-Tetrahydrocannabinol pharmaceuticals Review A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of D9-Tetrahydrocannabinol Salahaden R. Sultan 1,2, Sophie A. Millar 1 ID , Saoirse E. O’Sullivan 1 and Timothy J. England 1,* ID 1 Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Derby DE22 3DT, UK; [email protected] (S.R.S.); [email protected] (S.A.M.); [email protected] (S.E.O.) 2 Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia * Correspondence: [email protected]; Tel.: +44-1332-724668 Received: 4 December 2017; Accepted: 26 January 2018; Published: 31 January 2018 Abstract: D9-Tetrahydrocannabinol (THC) has complex effects on the cardiovascular system. We aimed to systematically review studies of THC and haemodynamic alterations. PubMed, Medline, and EMBASE were searched for relevant studies. Changes in blood pressure (BP), heart rate (HR), and blood flow (BF) were analysed using the Cochrane Review Manager Software. Thirty-one studies met the eligibility criteria. Fourteen publications assessed BP (number, n = 541), 22 HR (n = 567), and 3 BF (n = 45). Acute THC dosing reduced BP and HR in anaesthetised animals (BP, mean difference (MD) −19.7 mmHg, p < 0.00001; HR, MD −53.49 bpm, p < 0.00001), conscious animals (BP, MD −12.3 mmHg, p = 0.0007; HR, MD −30.05 bpm, p < 0.00001), and animal models of stress or hypertension (BP, MD −61.37 mmHg, p = 0.03) and increased cerebral BF in murine stroke models (MD 32.35%, p < 0.00001). Chronic dosing increased BF in large arteries in anaesthetised animals (MD 21.95 mL/min, p = 0.05) and reduced BP in models of stress or hypertension (MD −22.09 mmHg, p < 0.00001). In humans, acute administration increased HR (MD 8.16 bpm, p < 0.00001). THC acts differently according to species and experimental conditions, causing bradycardia, hypotension and increased BF in animals; and causing increased HR in humans. Data is limited, and further studies assessing THC-induced haemodynamic changes in humans should be considered. Keywords: D9-Tetrahydrocannabinol; THC; cardiovascular system; blood pressure; heart rate; blood flow 1. Introduction D9-Tetrahydrocannabinol (THC) is the most abundant and widely studied phytocannabinoid, first discovered in 1964 [1]. THC is a partial agonist of both cannabinoid receptors CB1 and CB2 and other targets including G protein-coupled receptors GPR55 and GPR18 [2–4]. THC possesses interesting therapeutic potential as an antiemetic, appetite stimulant, and analgesic, and for the treatment of glaucoma, epilepsy, Parkinson‘s disease, and multiple sclerosis [5–7]. THC has been shown to be effective against refractory nausea and vomiting in cancer patients undergoing chemotherapy [8]. However, its use as a therapeutic agent is limited by its recognised psychogenic side effects including hallucinations, euphoria, dizziness, mood changes, nausea, and fatigue [8–10]. THC has numerous cardiovascular effects in animals and humans. In vitro studies have shown that THC causes endothelium-independent vasorelaxation of rabbit superior mesenteric arteries [11] and vasorelaxation of the rat mesenteric artery through sensory nerves via a CB1 and CB2 receptor-independent mechanism [12]. Other studies have found THC to activate a G Pharmaceuticals 2018, 11, 13; doi:10.3390/ph11010013 www.mdpi.com/journal/pharmaceuticals Pharmaceuticals 2018, 11, 13 2 of 19 Pharmaceuticals 2018, 11, x FOR PEER REVIEW 2 of 19 protein-coupled receptor, inhibit calcium channels, and activate potassium channels in the rat Inmesenteric contrast,vasculature other studies [13 have] and shown to cause that endothelium-dependent THC causes vasoconstriction and time-dependent in guinea pig vasorelaxation pulmonary arteriesin the rat [16] aorta, rat [mesenteric14,15]. In contrast, arteries and other aorta studies [14,17] have, and shown rabbit that ear THCarteries causes [18]. vasoconstriction in guineaIn pigvivo pulmonary studies arterieshave reported [16], rat mesentericdifferent arterieshaemodynamic and aorta responses [14,17], and post rabbit-THC. ear arteriesAn acute [18]. administrationIn vivo studies of THC have caused reported hypotension different and haemodynamicbradycardia in anesthetised responses post-THC. dogs (intravenously; An acute i.v.),administration conscious bats of THC (intraperitoneal; caused hypotension i.p.), and and humans bradycardia (oral) [19 in– anesthetised21]. In contrast, dogs tachycardia (intravenously; and hypertensioni.v.), conscious were bats reported (intraperitoneal; in rats after i.p.), i.p. and administration humans (oral) of THC [19–21 [22,23]]. In contrast,. More complex tachycardia effects and on BPhypertension were induced were by reportedTHC in anaesthetised in rats after i.p.rats administration[24]. The available of THCevidence [22,23 to]. date More suggests complex that effects THC alterson BP the were haemodynamics induced by THC in in animals anaesthetised and humans, rats [24 ].albeit The availablewith conflicting evidence results to date variable suggests with that species,THC alters route the of haemodynamics administration, inand animals experimental and humans, conditions. albeit withTherefore, conflicting the aim results this variablestudy was with to systematicallyspecies, route ofreview administration, and meta- andanalyse experimental the in vivo conditions. literature assessing Therefore, the the effects aim this of studyTHC on was the to cardiovascularsystematically reviewsystem in and all meta-analyse species under the different in vivo conditions. literature assessing the effects of THC on the cardiovascular system in all species under different conditions. 2. Results 2. Results From the initial 2743 search results, 1935 relevant publications were identified and evaluated from Fromthree thedatabases initial2743 (Medline, search EMBASE, results, 1935 and relevant PubMed). publications Of these, 30 were articles identified met the and inclusion evaluated criteria from andthree 1 databases article was (Medline, added manually EMBASE, (Figure and PubMed). 1). A summary Of these, 30of articlesthe data met extracted the inclusion from the criteria included and 1 studiesarticle was is shown added in manually Table 1. (Figure1). A summary of the data extracted from the included studies is shown in Table1. Figure 1. Flow chart for study retrieval and selection. Figure 1. Flow chart for study retrieval and selection. Pharmaceuticals 2018, 11, 13 3 of 19 Table 1. Summary of the included studies divided according to the experimental conditions. Author & Species, Model Time of THC Time of Haemodynamic Basal Study Description Sample Size THC Dose THC Route Outcomes and Comments Year (Anaesthetic & Route) Administration Measurements Parameters * Anaesthetised animals Investigate the THC altered distribution of Cavero Dogs Anaesthetised Continues for 30 m haemodynamic 11 2.5 mg/kg i.v. Post-anaesthesia - regional BF, and reduced HR 1972 [25] (pentobarbital, iv) post-drug effects of THC and BP. C: HR:169, Investigate the THC caused reduction in HR Cavero Dogs Anaesthetised Continues for 2 h BP:91.7; T: haemodynamic 23 39 µg/kg–2.5 mg/kg i.v. Post-anaesthesia and BP mediated via central 1973a [26] (pentobarbital, iv) post-drug HR:165.7, effects of THC nervous system. BP:93.5 Characterise the THC induced reduction in HR Cavero mechanism of Dogs Anaesthetised Continues for 140 m 29 39 µg/kg–5 mg/kg i.v. Post-anaesthesia - through alteration of autonomic 1973b [27] action of THC (pentobarbital, iv) post-drug innervation to myocardium. on HR Investigate the Dogs (heart bypass) C: HR:156, THC caused reduction in HR Cavero Pre-drug and continues effect of THC on Anaesthetised 8 2.5 mg/kg i.v. Post-anaesthesia BP:85.8; T: and BP, and reduced 1974 [19] for 30 m post-drug venous return (dibucaine, spinal) HR:147, BP:85. venous return. Investigate the THC reduced HR and BP Daskalopoulos Cats Anaesthetised mechanism of THC 40 30–300 µg/kg i.v. Post-anaesthesia 20 m post-drug - mediated via central 1975 [28] (urethane, iv) on CV system nervous system. THC caused reduction in HR C: HR:316.2, and biphasic BP response (" BP Adams Examined the CV Rats Anaesthetised Continues for 30 min BP:76.2; T: 72 0.1–3 mg/kg i.v. Post-anaesthesia followed by # BP), suggesting 1976 [29] effects of THC (urethane, ip) post-drug HR:314.8, that THC depressed CV BP:73.5. reflex functions. Chronic THC antagonised the Evaluated possible Twice/day for Jandhyala Dogs Anaesthetised On the 7th day elevation in HR induced by the interaction with 12 1 mg/kg s.c. 7 days - 1976 [30] (pentobarbital) post-anaesthesia anaesthetic agent via THC on HR Pre-anaesthesia vagal stimulation. Determined chronic Twice/day for Jandhyala administration of Dogs Anaesthetised On the 7th day Chronic THC had no effect on 16 1 mg/kg s.c. 7 days - 1977 [31] THC on (pentobarbital) post-anaesthesia haemodynamics. Pre-anaesthesia CV function Investigated Chronic THC increased BF in Jandhyala prolonged THC Dogs Anaesthetised Single dose per On the 35th day 16 2 mg/kg s.c. - femoral and mesenteric arteries 1978 [32] effects on (pentobarbital) day for 35 days post-anaesthesia with no effect on HR or BP. CV system Examined the Cats Anaesthetised THC had no effect in stimulated McConnell Continues for 1 h effects of THC on (urethane & 20 0.1–2 mg/kg i.v. Post-anaesthesia - salivary flow of cats. THC 1978 [33] post-drug salivary flow pentobarbital, ip) caused a reduction in HR and BP. Pharmaceuticals 2018, 11, 13 4 of 19 Table 1. Cont. Author & Species, Model Time of THC Time of Haemodynamic Basal Study Description Sample Size THC Dose THC Route Outcomes and Comments Year (Anaesthetic & Route) Administration Measurements Parameters * Anaesthetised animals THC induced triphasic BP response (# BP via vagal stimulation, then " BP not Siqueira Clarify the triple BP Rats Anaesthetised Continues for 70 m 50 1–10 mg/kg i.v. Post-anaesthesia - dependent on sympathetic 1979 [24] response post-THC (urethane, ip) post-drug activity followed by # BP due to central decrease in sympathetic tone).
Load more

Recommended publications
  • 2 Spice English Presentation
    Spice Spice contains no compensatory substances Специи не содержит компенсационные вещества Spice is a mix of herbs (shredded plant material) and manmade chemicals with mind-altering effects. It is often called “synthetic marijuana” because some of the chemicals in it are similar to ones in marijuana; but its effects are sometimes very different from marijuana, and frequently much stronger. It is most often labeled “Not for Human Consumption” and disguised as incense. Eliminationprocess • The synthetic agonists such as THC is fat soluble. • Probably, they are stored as THC in cell membranes. • Some of the chemicals in Spice, however, attach to those receptors more strongly than THC, which could lead to a much stronger and more unpredictable effect. • Additionally, there are many chemicals that remain unidentified in products sold as Spice and it is therefore not clear how they may affect the user. • Moreover, these chemicals are often being changed as the makers of Spice alter them to avoid the products being illegal. • To dissolve the Spice crystals Acetone is used endocannabinoids synhtetic THC cannabinoids CB1 and CB2 agonister Binds to cannabinoidreceptor CB1 CB2 - In the brain -in the immune system Decreased avtivity in the cell ____________________ Maria Ellgren Since some of the compounds have a longer toxic effects compared to naturally THC, as reported: • negative effects that often occur the day after consumption, as a general hangover , but without nausea, mentally slow, confused, distracted, impairment of long and short term memory • Other reports mention the qualitative impairment of cognitive processes and emotional functioning, like all the oxygen leaves the brain.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • WO 2018/018152 Al 01 February 2018 (01.02.2018) W !P O IPCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/018152 Al 01 February 2018 (01.02.2018) W !P O IPCT (51) International Patent Classification: A61K 9/68 (2006 .0 1) A61P 25/04 (2006 .0 1) A61K 31/05 (2006.01) C07C 39/23 (2006.01) A61K 31/352 (2006.01) C07D 311/80 (2006.01) (21) International Application Number: PCT/CA20 17/050904 (22) International Filing Date: 28 July 2017 (28.07.2017) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 15/222,019 28 July 2016 (28.07.2016) US (72) Inventor; and (71) Applicant: GREENSPOON, Allen [CA/CA]; Ml-414 Victoria Avenue South, Hamilton, Ontario L8L 5G8 (CA). (74) Agent: TANDAN, Susan; Gowling WLG (Canada) LLP, One Main Street West, Hamilton, Ontario L8P 4Z5 (CA). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Structure-Activity Relationships of the Cannabinoids
    RESEARCH ANALYSIS and UTILIZATION SYSTEM Structure-Activity Relationships of the Cannabinoids DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration Structure-Activity Relationships of the Cannabinoids Editors: Rao S. Rapaka, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Alexandros Makriyannis, Ph.D. School of Pharmacy and Institute of Materials Science University of Connecticut and F. Bitter National Magnet Laboratory Massachusetts Institute of Technology NIDA Research Monograph 79 A RAUS Review Report 1987 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. MARY L. JACOBSON Temple University School of Medicine National Federation of Parents for Philadelphia, Pennsylvania Drug-Free Youth Omaha, Nebraska SYDNEY ARCHER, Ph.D. Rensselaer Polytechnic lnstitute Troy, New York REESE T. JONES, M.D. Langley Porter Neuropsychiatric Institute RICHARD E. BELLEVILLE, Ph.D. San Francisco, California NB Associates. Health Sciences Rockville, Maryland DENISE KANDEL, Ph.D. KARST J. BESTEMAN College of Physicians and Surgeons of Alcohol and Drug Problems Association Columbia University of North America New York, New York Washington, D.C.
    [Show full text]
  • House Committee Substitute for Senate Substitute for Senate Committee Substitute for Senate Bill No
    SECOND REGULAR SESSION HOUSE COMMITTEE SUBSTITUTE FOR SENATE SUBSTITUTE FOR SENATE COMMITTEE SUBSTITUTE FOR SENATE BILL NO. 547 99TH GENERAL ASSEMBLY 5165H.07C D. ADAM CRUMBLISS, Chief Clerk AN ACT To repeal sections 195.010, 195.017, and 196.070, RSMo, and to enact in lieu thereof sixteen new sections relating to industrial hemp, with penalty provisions. Be it enacted by the General Assembly of the state of Missouri, as follows: Section A. Sections 195.010, 195.017, and 196.070, RSMo, are repealed and sixteen new 2 sections enacted in lieu thereof, to be known as sections 195.010, 195.017, 195.203, 195.740, 3 195.743, 195.746, 195.749, 195.752, 195.755, 195.756, 195.758, 195.764, 195.767, 195.770, 4 195.773, and 196.070, to read as follows: 195.010. The following words and phrases as used in this chapter and chapter 579, 2 unless the context otherwise requires, mean: 3 (1) "Addict", a person who habitually uses one or more controlled substances to such an 4 extent as to create a tolerance for such drugs, and who does not have a medical need for such 5 drugs, or who is so far addicted to the use of such drugs as to have lost the power of self-control 6 with reference to his or her addiction; 7 (2) "Administer", to apply a controlled substance, whether by injection, inhalation, 8 ingestion, or any other means, directly to the body of a patient or research subject by: 9 (a) A practitioner (or, in his or her presence, by his or her authorized agent); or 10 (b) The patient or research subject at the direction and in the presence of the practitioner; 11 (3) "Agent", an authorized person who acts on behalf of or at the direction of a 12 manufacturer, distributor, or dispenser.
    [Show full text]
  • INFORMATION to USERS the Most Advanced Technology Has Been Used to Photo­ Graph and Reproduce This Manuscript from the Microfilm Master
    Synthesis of cannabidiol stereoisomers and analogs as potential anticonvulsant agents. Item Type text; Dissertation-Reproduction (electronic) Authors Shah, Vibhakar Jayantilal. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 02/10/2021 14:16:58 Link to Item http://hdl.handle.net/10150/184523 INFORMATION TO USERS The most advanced technology has been used to photo­ graph and reproduce this manuscript from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely eve~~t that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are re­ produced by sectioning the original, beginni'ng at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book.
    [Show full text]
  • Model Scheduling New Novel Psychoactive Substances
    Model Scheduling New/Novel Psychoactive Substances Act September 2018 (original version published in 2014). This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2018. NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non- commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact Jon Woodruff at [email protected] or (703) 836-7496 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE 1 FOR MODEL STATE DRUG LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 12 Section IV – Substituted Cathinones 18 Section V – Substituted Phenethylamines 22 Section VI – N-benzyl Phenethylamine Compounds 24 Section VII – Substituted Tryptamines 27 Section VIII – Substituted Phenylcyclohexylamines 28 Section IX – Fentanyl Derivatives 37 Section X – Unclassified NPS © 2018. NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non- commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact Jon Woodruff at [email protected] or (703) 836-7496 with any questions about the Model Language.
    [Show full text]
  • Investigator Mark Dungy Winona County Sheriff's Office S.E.M.N.T.F
    Investigator Mark Dungy Winona County Sheriff’s Office S.E.M.N.T.F. Synthetic Drugs MDPV turbo or bath salts Mephedrone plant food Synthetic Cannabinoids fake weed, fake pot, spice, Deja-Vu, or Kryptonite Overview MDPV or Mephedrone Synthetic Cannabinoids Methods of Ingestion Smoked (MDPV) Smoked Painted on Foil Pipes Pipes Bongs Crumbled on Foil Inhaled Snorted Injected More Common MDPV and Mepherdrone Synthetic Cannabinoids MDPV 2011 C 53 (6) Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such the salts, isomers, and salts of isomers is possible within the specific chemical designation: methylenedioxypyrovalerone (MDPV). Sale M.S.S. 152.024, subd. 1(1) Possession M.S.S. 152.025, subd. 2(a)(1) Mephedrone 2011 C 53 Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such the salts, isomers, and salts of isomers is possible within the specific chemical designation: Cathinone; Methcathinone; 4- methylmethcathinone (mephedrone); 3,4-methylenedioxy-N- methylcathinone (methylone); 4- methoxymethcathinone (methedrone) Sale M.S.S. 152.024, subd. 1(1) Possession M.S.S. 152.025, subd. 2 (a)(1) Synthetic Cannabinoids 152.027 OTHER CONTROLLED SUBSTANCE OFFENSES. Subd. 6.Sale or possession of synthetic cannabinoids.
    [Show full text]
  • House Bill No. 2038
    SECOND REGULAR SESSION HOUSE COMMITTEE SUBSTITUTE FOR HOUSE BILL NO. 2038 98TH GENERAL ASSEMBLY 5338H.02C D. ADAM CRUMBLISS, Chief Clerk AN ACT To repeal sections 195.010 and 195.017 as enacted by senate bill no. 491, ninety-seventh general assembly, second regular session, and sections 195.010 and 195.017 as enacted by house bill no. 641, ninety-sixth general assembly, first regular session, and to enact in lieu thereof seven new sections relating to industrial hemp, with penalty provisions. Be it enacted by the General Assembly of the state of Missouri, as follows: Section A. Sections 195.010 and 195.017 as enacted by senate bill no. 491, 2 ninety-seventh general assembly, second regular session, and sections 195.010 and 195.017 as 3 enacted by house bill no. 641, ninety-sixth general assembly, first regular session are repealed 4 and seven new sections enacted in lieu thereof, to be known as sections 195.010, 195.017, 5 195.203, 195.600, 195.603, 195.606, and 195.609, to read as follows: 195.010. The following words and phrases as used in this chapter and chapter 579, 2 unless the context otherwise requires, mean: 3 (1) "Addict", a person who habitually uses one or more controlled substances to such an 4 extent as to create a tolerance for such drugs, and who does not have a medical need for such 5 drugs, or who is so far addicted to the use of such drugs as to have lost the power of self-control 6 with reference to his or her addiction; 7 (2) "Administer", to apply a controlled substance, whether by injection, inhalation, 8 ingestion, or any other means, directly to the body of a patient or research subject by: 9 (a) A practitioner (or, in his or her presence, by his or her authorized agent); or 10 (b) The patient or research subject at the direction and in the presence of the practitioner; 11 (3) "Agent", an authorized person who acts on behalf of or at the direction of a 12 manufacturer, distributor, or dispenser.
    [Show full text]
  • Controlled Chemical Substances Established in Lists I and II Of
    Controlled chemical substances established in lists I and II of Appendix I of the Organic Law of Drugs (Official Gazette 39,546 of 11-05-2010) LIST II Acetone LIST I Anthranilic acid N - Acetylanthranilic acid Hydrochloric acid Lysergic acid Phenylacetic acid Ephedrine Sulfuric acid* Ergometrine Diethyl ether Ergotamine Methyl Ethyl Ketone (MEK) 1-phenylpropane-2-one Piperidine Isosafrole Toluene* 3,4-Metilenodioxifenil-2- Anhydrous ammonia Propanone Ammonia Dissolution Piperonal Watery Safrole Sodium carbonate Pseudoephedrine Hydrogencarbonate Norephedrine Sodium bicarbonate Phenylpropanolamine Sodium sesquicarbonate Potassium permanganate* 4-Methylpentan-2-one (MIBK) Acetic anhydride Ethyl acetate The most common medicines published in the list issued by the Psychotropic Substances of the International Narcotics Control Board (INCB) are shown below, this pursuant to article 3, numeral 29 of the Organic Labor Law referred to the psychotropic substances of 1971 endorsed by Venezuela. It includes medicines that allegedly stand as a serious risk for public health and List I which therapeutic value remains unknown for the Commission on Narcotic Drugs (CND). It includes psychedelic synthetics like LSD, besides the natural ones like isomers DMT. The MDMA, commonly called ectasy, also belongs to this category. Stimulants like amphetamines belong to this category; it is considered they have a List II limited therapeutic value, as well as some analgesic like morphine. Drobinol, as a THC isomer, is also included. Barbiturate of medium and fast effects, which have been consumed in excess, List III despite their therapeutic use, like Flunitrazepam and some analgesics like buprenorphine. It includes weaker and hypnotic barbiturate, hypnotic anxiolytics, List IV benzodiazepines, THC, as well as stimulants with weaker effects.
    [Show full text]
  • Schedules of Controlled Substances in Conflict Herewith Are Hereby Repealed
    Pursuant to the provisions of Arkansas Code Annotated § 5-64-201 and § 5-64-216 of the laws of the State of Arkansas, the Director of the Arkansas Department of Health or duly authorized agent, as specified by law, is giving public notice of the publication of the List of Controlled Substances for the State of Arkansas. Due consideration has been given applicable federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability. Based on these considerations the attached listing of the Schedule of Controlled Substances and the corresponding drugs that are included in each schedule is hereby promulgated by the Director of the Arkansas Department of Health as the List of Controlled Substances for the State of Arkansas. Each controlled substance or basic class thereof has been assigned an “Administration Controlled Substance Code Number” for purposes of identification. These numbers are for internal management and are used as a means to identify substances with complex and cumbersome chemical names. Next to the code number is the date the substance was placed in schedule by the Director of the Arkansas Department of Health. I, James Myatt, P.D., Branch Chief of Pharmacy Services for the Arkansas Department of Health, do hereby certify that the documents attached hereto are true and correct copies of the current List of Controlled Substances adopted by the Arkansas State Board of Health in accordance with Arkansas state law.
    [Show full text]